Verrica Pharmaceuticals (NASDAQ:VRCA) Posts Quarterly Earnings Results

Verrica Pharmaceuticals (NASDAQ:VRCA) posted its quarterly earnings results on Monday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12), Zacks reports. The firm had revenue of ($1.78) million for the quarter, compared to the consensus estimate of $7.53 million. Verrica Pharmaceuticals had a negative return on equity of 3,102.90% and a negative net margin of 625.06%.

Verrica Pharmaceuticals Stock Down 3.3 %

Shares of VRCA traded down $0.02 during midday trading on Thursday, hitting $0.72. 163,354 shares of the company’s stock traded hands, compared to its average volume of 453,404. The firm’s fifty day moving average is $1.64 and its 200-day moving average is $5.14. The company has a current ratio of 2.36, a quick ratio of 2.23 and a debt-to-equity ratio of 29.58. Verrica Pharmaceuticals has a 1 year low of $0.71 and a 1 year high of $11.41. The stock has a market capitalization of $30.79 million, a price-to-earnings ratio of -0.41 and a beta of 1.45.

Analyst Ratings Changes

Several brokerages have issued reports on VRCA. Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Tuesday. Brookline Capital Management reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, October 2nd. Royal Bank of Canada downgraded shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $11.00 to $2.00 in a research note on Tuesday. TD Cowen dropped their target price on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, October 21st. Finally, HC Wainwright downgraded Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Verrica Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $9.60.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.